Lupin gets USFDA nod for Rufinamide Oral Suspension

Rufinamide Oral Suspension, 40 mg/mL

Picture: Pixabay

Last Updated on December 23, 2020 by The Health Master

Lupin announced it has received approval for its Rufinamide Oral Suspension, 40 mg/mL, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Banzel Oral Suspension, 40 mg/ml, of Eisai Inc.

Rufinamide Oral Suspension, 40 mg/mL is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in pediatric patients one year of age and older, and in adults.

Rufinamide Oral Suspension, 40 mg/ mL (RLD: Banzel) had estimated annual sales of $124.5 million in the US (IQVIA MAT September 2020).

Also read | India to produce 300 million Sputnik V vaccines

The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.

Follow and connect with us on Facebook, Linkedin